Q1FY27 saw robust revenue and EBITDA growth, led by semaglutide launches and biologics momentum. Capacity expansion is on track, with a second cartridge line set for Q2 and a reaffirmed FY28 revenue outlook of $400m. EBITDA margin and customer base continue to strengthen.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.